In Vitro MCF-7 Cells Apoptosis Analysis of Carboplatin Loaded Silk Fibroin Particles.

Nanyak Galam,Terin Adali,Pinar Tulay

doi:10.3390/molecules25051110

Abstract

Breast cancer ranks as the fifth leading cause of death worldwide. Chemotherapy is commonly used directly or as neo-adjuvant therapy for the management of breast cancer with its attendant adverse effects, underscoring the need to develop biocompatible bioactive compounds for pharmacological applications. The aim of this study is to encapsulate carboplatin (CP) with silk fibroin protein (SF) by using an ionic gelation method as a drug carrier system and assess the apoptotic effect on MCF-7 breast cancer cells during in vitro studies. The characterization of silk fibroin encapsulated carboplatin (SFCP) microparticles was analyzed by FTIR spectrophotometer, SEM, Mastersizer, and biodegradation methods. The encapsulation efficiency and release profile of SFCP microparticles were analyzed by an indirect UV–Vis spectrophotometric method. An apoptotic screening of MCF-7 cells was carried out with 10–200 µg/mL CP loaded SFCP, which were cultured for 24, 48, and 72 h. Data were analyzed using the Student’s t test and analysis of variance. FTIR and drug release studies confirmed an interaction of silk fibroin with the carboplatin moiety. SFCP showed successful encapsulation of the carboplatin moiety. Apoptotic screening showed a dose dependent increase in absorbance, indicating significant cell death (p < 0.05). Thus, the direct apoptotic effect of SFCP microparticles on MCF-7 was confirmed.

Highlights

Breast cancer is the second most diagnosed cancer in women in both developed and developing countries
This study is limited by the use of one breast cancer cell line, it has shown that
Its encapsulation was confirmed via an indirect method described by Basotra [31], and an Fourier Transform Infrared Spectroscopy (FTIR) showed the characteristic features of silk fibroin protein (SF) interacting with carboplatin

Summary

Introduction

Breast cancer is the second most diagnosed cancer in women in both developed and developing countries. It is estimated that over 2.09 million cases exist worldwide and that 627,000 women passed away in 2018 [1]. There are problems associated with chemotherapeutic therapies as a result of acquired resistance as well as drug toxicity [4]. Designing chemotherapeutic drug delivery systems is very important for effective cancer treatment. Studies focusing on targetable drug delivery systems for breast cancer treatment have gained in importance [5,6]. The outcomes after breast cancer treatment have improved, the drawbacks such as side effects are still a major issue [7,8]. The pro-drug approach causes a loss of stability and drug activity after modification

Objectives

Methods

Results

Conclusion